Pacira Pharmaceuticals Inc (PCRX) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/pacira_pharmaceuticals_inc_pcrx_financial_n_strategic_swot_analysis_review_en.gif)
Pacira Pharmaceuticals Inc (PCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its other products developed under partnerships include DepoCyt (cytarabine liposome injection) for lymphomatous meningitis; and Nocita (bupivacaine liposome injectable suspension) for surgical infiltration in dogs. Its products are used by hospitals and ambulatory surgery centers. The company sells its products through co-promotion agreements and supply agreements with other pharmaceutical companies. Pacira is headquartered in Parsippany, New Jersey, the US.
Pacira Pharmaceuticals Inc Key Recent Developments
Apr 02,2019 Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Mar 06,2019 Pacira to acquire medical device maker Myoscience for $220m
Feb 28,2019 Pacira reports record fourth quarter and full year revenues
Feb 12,2019 Pacira Pharmaceuticals Expands Manufacturing in UK
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its other products developed under partnerships include DepoCyt (cytarabine liposome injection) for lymphomatous meningitis; and Nocita (bupivacaine liposome injectable suspension) for surgical infiltration in dogs. Its products are used by hospitals and ambulatory surgery centers. The company sells its products through co-promotion agreements and supply agreements with other pharmaceutical companies. Pacira is headquartered in Parsippany, New Jersey, the US.
Pacira Pharmaceuticals Inc Key Recent Developments
Apr 02,2019 Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Mar 06,2019 Pacira to acquire medical device maker Myoscience for $220m
Feb 28,2019 Pacira reports record fourth quarter and full year revenues
Feb 12,2019 Pacira Pharmaceuticals Expands Manufacturing in UK
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Pacira Pharmaceuticals Inc - Key Facts
Pacira Pharmaceuticals Inc - Key Employees
Pacira Pharmaceuticals Inc - Key Employee Biographies
Pacira Pharmaceuticals Inc - Major Products and Services
Pacira Pharmaceuticals Inc - History
Pacira Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Pacira Pharmaceuticals Inc - Business Description
Product Category: Exparel
Overview
Performance
Product Category: Other Products
Overview
Performance
R&D Overview
Pacira Pharmaceuticals Inc - Corporate Strategy
Pacira Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Pacira Pharmaceuticals Inc - Strengths
Pacira Pharmaceuticals Inc - Weaknesses
Pacira Pharmaceuticals Inc - Opportunities
Pacira Pharmaceuticals Inc - Threats
Pacira Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Apr 02, 2019: Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Mar 06, 2019: Pacira to acquire medical device maker Myoscience for $220m
Feb 28, 2019: Pacira reports record fourth quarter and full year revenues
Feb 12, 2019: Pacira Pharmaceuticals Expands Manufacturing in UK
Feb 12, 2019: Pacira expands EXPAREL Manufacturing Capacity to meet growing demand
Nov 16, 2018: Pacira Pharmaceuticals CMO presents at FDA advisory committee meeting focused on assessment of opioid-sparing outcomes in clinical trials
Nov 01, 2018: Pacira Pharmaceuticalsb reports third quarter 2018 financial results
Aug 02, 2018: Pacira Pharmaceuticals reports second quarter 2018 financial results
Jul 10, 2018: Pacira Reports Preliminary Net EXPAREL Sales of $80.4 Million for Second Quarter of 2018
Jun 13, 2018: MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS) Collaborative to Minimize Opioid Use
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Pacira Pharmaceuticals Inc - Key Facts
Pacira Pharmaceuticals Inc - Key Employees
Pacira Pharmaceuticals Inc - Key Employee Biographies
Pacira Pharmaceuticals Inc - Major Products and Services
Pacira Pharmaceuticals Inc - History
Pacira Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Pacira Pharmaceuticals Inc - Business Description
Product Category: Exparel
Overview
Performance
Product Category: Other Products
Overview
Performance
R&D Overview
Pacira Pharmaceuticals Inc - Corporate Strategy
Pacira Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Pacira Pharmaceuticals Inc - Strengths
Pacira Pharmaceuticals Inc - Weaknesses
Pacira Pharmaceuticals Inc - Opportunities
Pacira Pharmaceuticals Inc - Threats
Pacira Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Apr 02, 2019: Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Mar 06, 2019: Pacira to acquire medical device maker Myoscience for $220m
Feb 28, 2019: Pacira reports record fourth quarter and full year revenues
Feb 12, 2019: Pacira Pharmaceuticals Expands Manufacturing in UK
Feb 12, 2019: Pacira expands EXPAREL Manufacturing Capacity to meet growing demand
Nov 16, 2018: Pacira Pharmaceuticals CMO presents at FDA advisory committee meeting focused on assessment of opioid-sparing outcomes in clinical trials
Nov 01, 2018: Pacira Pharmaceuticalsb reports third quarter 2018 financial results
Aug 02, 2018: Pacira Pharmaceuticals reports second quarter 2018 financial results
Jul 10, 2018: Pacira Reports Preliminary Net EXPAREL Sales of $80.4 Million for Second Quarter of 2018
Jun 13, 2018: MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS) Collaborative to Minimize Opioid Use
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Pacira Pharmaceuticals Inc, Key Facts
Pacira Pharmaceuticals Inc, Key Employees
Pacira Pharmaceuticals Inc, Key Employee Biographies
Pacira Pharmaceuticals Inc, Major Products and Services
Pacira Pharmaceuticals Inc, History
Pacira Pharmaceuticals Inc, Other Locations
Pacira Pharmaceuticals Inc, Subsidiaries
Pacira Pharmaceuticals Inc, Key Competitors
Pacira Pharmaceuticals Inc, Ratios based on current share price
Pacira Pharmaceuticals Inc, Annual Ratios
Pacira Pharmaceuticals Inc, Annual Ratios (Cont...1)
Pacira Pharmaceuticals Inc, Annual Ratios (Cont...2)
Pacira Pharmaceuticals Inc, Interim Ratios
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Pacira Pharmaceuticals Inc, Key Facts
Pacira Pharmaceuticals Inc, Key Employees
Pacira Pharmaceuticals Inc, Key Employee Biographies
Pacira Pharmaceuticals Inc, Major Products and Services
Pacira Pharmaceuticals Inc, History
Pacira Pharmaceuticals Inc, Other Locations
Pacira Pharmaceuticals Inc, Subsidiaries
Pacira Pharmaceuticals Inc, Key Competitors
Pacira Pharmaceuticals Inc, Ratios based on current share price
Pacira Pharmaceuticals Inc, Annual Ratios
Pacira Pharmaceuticals Inc, Annual Ratios (Cont...1)
Pacira Pharmaceuticals Inc, Annual Ratios (Cont...2)
Pacira Pharmaceuticals Inc, Interim Ratios
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Pacira Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Pacira Pharmaceuticals Inc, Ratio Charts
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
DURECT Corp
Akorn Inc
AcelRx Pharmaceuticals Inc
Roche Holding, Ltd.
Scilex Pharmaceuticals Inc
Napp Pharmaceuticals Ltd
Kimberly-Clark Corporation
Pacira Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Pacira Pharmaceuticals Inc, Ratio Charts
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
DURECT Corp
Akorn Inc
AcelRx Pharmaceuticals Inc
Roche Holding, Ltd.
Scilex Pharmaceuticals Inc
Napp Pharmaceuticals Ltd
Kimberly-Clark Corporation